DE68919504T2 - Beschleunigung der Lyse von Gerinnsel. - Google Patents

Beschleunigung der Lyse von Gerinnsel.

Info

Publication number
DE68919504T2
DE68919504T2 DE68919504T DE68919504T DE68919504T2 DE 68919504 T2 DE68919504 T2 DE 68919504T2 DE 68919504 T DE68919504 T DE 68919504T DE 68919504 T DE68919504 T DE 68919504T DE 68919504 T2 DE68919504 T2 DE 68919504T2
Authority
DE
Germany
Prior art keywords
clot lysis
hapten
binding molecule
thrombolytic agent
preventing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE68919504T
Other languages
English (en)
Other versions
DE68919504D1 (de
Inventor
Guy L Reed
Gary Matsueda
Edgar Haber
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of DE68919504D1 publication Critical patent/DE68919504D1/de
Application granted granted Critical
Publication of DE68919504T2 publication Critical patent/DE68919504T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Surgical Instruments (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE68919504T 1988-04-04 1989-04-04 Beschleunigung der Lyse von Gerinnsel. Expired - Fee Related DE68919504T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US17722288A 1988-04-04 1988-04-04

Publications (2)

Publication Number Publication Date
DE68919504D1 DE68919504D1 (de) 1995-01-12
DE68919504T2 true DE68919504T2 (de) 1995-06-29

Family

ID=22647707

Family Applications (1)

Application Number Title Priority Date Filing Date
DE68919504T Expired - Fee Related DE68919504T2 (de) 1988-04-04 1989-04-04 Beschleunigung der Lyse von Gerinnsel.

Country Status (15)

Country Link
EP (1) EP0336693B1 (de)
JP (1) JP2871775B2 (de)
KR (1) KR100194113B1 (de)
AT (1) ATE114480T1 (de)
AU (1) AU628041B2 (de)
CA (1) CA1341377C (de)
DE (1) DE68919504T2 (de)
DK (1) DK174062B1 (de)
ES (1) ES2064435T3 (de)
FI (1) FI102812B1 (de)
GR (1) GR3015182T3 (de)
HU (1) HU207349B (de)
NO (1) NO301374B1 (de)
WO (1) WO1989009817A1 (de)
ZA (1) ZA892464B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5357042A (en) * 1984-04-23 1994-10-18 The General Hospital Corporation Synthetic peptides capable of eliciting fibrin-specific monoclonal antibodies lacking fibrinogen-cross-reactivity
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
US5582862A (en) * 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
JPH02268694A (ja) * 1989-04-07 1990-11-02 Teijin Ltd 血栓溶解剤
EP0937146A2 (de) * 1996-09-20 1999-08-25 The General Hospital Corporation Zusammensetzung und verfahren zur verstärkung von fibrinolyse unter verwendung von antikörpern gegen alpha2-antiplasmin
US6524675B1 (en) 1999-05-13 2003-02-25 3M Innovative Properties Company Adhesive-back articles

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0735340B2 (ja) * 1985-05-23 1995-04-19 帝人株式会社 血栓溶解促進剤
EP0266419B1 (de) * 1986-05-15 1994-03-02 Emory University Fibrinolytische zusammensetzung

Also Published As

Publication number Publication date
NO904294L (no) 1990-12-04
WO1989009817A1 (en) 1989-10-19
DK240190D0 (da) 1990-10-04
EP0336693A2 (de) 1989-10-11
NO301374B1 (no) 1997-10-20
CA1341377C (en) 2002-07-16
JP2871775B2 (ja) 1999-03-17
FI102812B (fi) 1999-02-26
FI904867A0 (fi) 1990-10-03
DE68919504D1 (de) 1995-01-12
HUT56394A (en) 1991-08-28
HU207349B (en) 1993-03-29
FI102812B1 (fi) 1999-02-26
ATE114480T1 (de) 1994-12-15
ZA892464B (en) 1989-12-27
KR100194113B1 (ko) 1999-06-15
GR3015182T3 (en) 1995-05-31
HU892304D0 (en) 1991-07-29
EP0336693A3 (en) 1990-03-21
JPH03504717A (ja) 1991-10-17
ES2064435T3 (es) 1995-02-01
DK174062B1 (da) 2002-05-13
AU628041B2 (en) 1992-09-10
EP0336693B1 (de) 1994-11-30
DK240190A (da) 1990-10-04
AU3284589A (en) 1989-11-03
KR900700129A (ko) 1990-08-11
NO904294D0 (no) 1990-10-03

Similar Documents

Publication Publication Date Title
DE3855096T2 (de) Hemmung von arteriellem thrombotischen Verschluss oder von Thrombo-Embolismus
DE68919504D1 (de) Beschleunigung der Lyse von Gerinnsel.
BR9708859A (pt) Composto uso do mesmo composição para inibir formação de trombo em sangue e processos para inibir trombina e formação de agregados de plaquetas sanguíneas e de trombo no sangue para tratar ou evitar tromboemolismo venoso e embolismo pulmonar trombose tromboembolismo cardiogênico acidente vascular cerebral trombose angina instável infartação miocárdica aterosclerose distúrbio cardaco isquêmico reoclus o restenose oclus o de enxertos de derivação de artéria coronária e doença cerebrovascular oclus
DK36991D0 (da) Vaevsplasminoaktivator-(t-pa)-variant med zymogene eller fibrinspecifikke eller plasmakoagel-specifikke egenskaber, fremgangsmaade til fremstilling deraf, dna-sekvens, som koder for varianten, replicerbar udtrykkelsesvektor for denne og vaertsceller transformeret med vektoren
GR3004568T3 (de)
DK0519903T3 (da) Lægemiddel indeholdende aktiveret protein C
ES2076965T3 (es) Activadores del plasminogeno salivares del murcielago vampiro.
ES2070116T3 (es) Peptidos que inhiben la union del factor von willebrand.
DE68919311T2 (de) Selbstinduzierte Reparatur von Leiterzügen.
ATE84724T1 (de) Gewisse paf-antagonist/antihistamin-mischungen und verfahren.
DE69023297D1 (de) Reduzierung des Säuregrads von Polyestern durch Endgruppenblockierung in der Schmelze mit Enaminen oder Schiffbasen.
ATE123057T1 (de) Trombolytischer wirkstoff mit modifikation der domäne der kringle.
DE3676490D1 (de) Vorbehandlungsverfahren von pulpe mit stabilisierungsmitteln und peroxid vor der mechanischen raffinierung.
VI PLATELET INHIBITORS IN ARTERIALTHROMBOSIS ANDATHEROCENESIS.
Jang et al. A randomized, blinded study of two doses of Novastan®(brand of argatroban) versus heparin as adjunctive therapy to recombinant tissue plasminogen activator (accelerated administration) in acute myocardial infarction: Rationale and design of the Myocardial Infarction using Novastan® and t-PA (MINT) study
ES2096617T3 (es) Uso de estafiloquinasa para la preparacion de una composicion farmaceutica para tratar trombosis arterial.
Norman III. INHIBITORS OF THE FIBRINOLYTIC SYSTEM
DE68912383T3 (de) Plasminogenaktivator und thrombolytischer Wirkstoff.
Konttinen The effect of streptokinase on the plasma heparin thrombin time
Rick et al. Activation of factor VIII by factor IXa.
ATE106733T1 (de) In der therapeutik anwendbare zusammensetzung mit aggregationshemmender wirkung auf blutplättchen.
BE604050A (fr) Fixation de rails, notamment pour voies de mines à rails inclinés.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee